Sepsis and atrial fibrillation: the role of amiodarone, alternative strategies and metabolic therapy. A systematic review
- 30 July 2026
- journal article
- review article
- Published by Media Sphere Publishing Group in Russian Journal of Cardiology and Cardiovascular Surgery
- Vol. 19 (4)
Abstract
Objective. To analyze the role of amiodarone, alternative rhythm and rate control strategies, and metabolic therapy in sepsis-associated atrial fibrillation (AF). Methods. A systematic search was conducted in PubMed/MEDLINE, Embase, Cochrane Library, and RSCI up to January 2026. Randomized controlled trials (RCTs), prospective and retrospective cohort studies (n≥30), and controlled experimental studies in adults with sepsis/septic shock and supraventricular tachyarrhythmias were included. Additionally, RCTs of succinate-containing and metabolic therapies in other critical conditions (acute myocardial infarction, cardiac surgery, stroke, severe traumatic brain injury) evaluating arrhythmic or mechanistically relevant endpoints were considered. Results. New-onset AF in sepsis is associated with a 2- to 3-fold increase in mortality. Amiodarone effectively controls rhythm and rate but does not improve survival in septic shock and carries risks of negative inotropy, hypotension, torsade de pointes, and organ toxicity. In an RCT, propafenone provided faster cardioversion and fewer AF recurrences compared to amiodarone with similar mortality; a survival benefit was observed in patients without significant left atrial dilatation. Short-acting β1-blockers (esmolol, landiolol) safely control heart rate in hyperdynamic shock. Simultaneous correction of hypokalemia and hypomagnesemia increases the likelihood of spontaneous cardioversion. Succinate-containing infusions (Reamberin) and Cytoflavin in RCTs for critical illness reduce reperfusion arrhythmias and improve left ventricular systolic function. Discussion. Evidence supporting propafenone and β-blockers is derived from a limited number of RCTs with heterogeneous inclusion criteria. Data on metabolic therapy in sepsis-associated AF are extrapolated from studies in other critical conditions (AMI, COVID-19). Direct multicenter RCTs of succinate-based therapies with arrhythmic endpoints in sepsis are lacking. Conclusion. In sepsis-associated AF, amiodarone should be reserved for patients with significant structural heart disease and left atrial dilatation. Propafenone and short-acting β1-blockers are preferable alternatives in patients without substantial myocardial remodeling. Succinate-containing and metabolic therapy is pathogenetically justified as an organ-protective adjuvant but requires dedicated RCTs in the sepsis population. Funding source. The authors declare no external funding.Keywords
This publication has 42 references indexed in Scilit:
- L-carnitine decreases myocardial injury in children undergoing open-heart surgery: A randomized controlled trialEuropean Journal of Pediatrics, 2024
- Propafenone versus amiodarone for supraventricular arrhythmias in septic shock: a randomised controlled trialIntensive Care Medicine, 2023
- Association of Intravenous Potassium and Magnesium Administration With Spontaneous Conversion of Atrial Fibrillation and Atrial Flutter in the Emergency DepartmentJAMA Network Open, 2022
- Sepsis-driven atrial fibrillation and ischaemic stroke. Is there enough evidence to recommend anticoagulation?European Journal of Internal Medicine, 2022
- Comparative Effectiveness of Heart Rate Control Medications for the Treatment of Sepsis-Associated Atrial FibrillationChest, 2021
- Cardiovascular Collapse with Intravenous Amiodarone in Children: A Multi-Center Retrospective Cohort StudyPediatric Cardiology, 2019
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Effect of Heart Rate Control With Esmolol on Hemodynamic and Clinical Outcomes in Patients With Septic ShockJAMA, 2013
- Cardioprotective Effect of Succinate Against Ischemia/Reperfusion InjurySurgery Today, 1998
- Effects of l-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the l-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) trialJACC, 1995